ATE242642T1 - Kombinationstherapie für lymphoproliferative krankheiten - Google Patents

Kombinationstherapie für lymphoproliferative krankheiten

Info

Publication number: ATE242642T1
Authority: AT; Austria
Prior art keywords: combination therapy; lymphoproliferative diseases; host; diseases; lymphoproliferative
Prior art date: 1999-02-24

Application number

AT00908300T

Other languages

English (en)

Inventor

John C Byrd

Michael R Grever

Ian W Flinn

Jamie K Waselenko

Original Assignee

Supergen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-24

Filing date

2000-01-19

Publication date

2003-06-15

2000-01-19 Application filed by Supergen Inc filed Critical Supergen Inc

2003-06-15 Application granted granted Critical

2003-06-15 Publication of ATE242642T1 publication Critical patent/ATE242642T1/de

Links

238000002648 combination therapy Methods 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000001589 lymphoproliferative effect Effects 0.000 title 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 abstract 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
208000030289 Lymphoproliferative disease Diseases 0.000 abstract 1
229940100198 alkylating agent Drugs 0.000 abstract 1
239000002168 alkylating agent Substances 0.000 abstract 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 abstract 1
229960002340 pentostatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT00908300T 1999-02-24 2000-01-19 Kombinationstherapie für lymphoproliferative krankheiten ATE242642T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/256,666 US6316435B2 (en)	1999-02-24	1999-02-24	Combination therapy for lymphoproliferative diseases
PCT/US2000/001180 WO2000050082A1 (en)	1999-02-24	2000-01-19	Combination therapy for lymphoproliferative diseases

Publications (1)

Publication Number	Publication Date
ATE242642T1 true ATE242642T1 (de)	2003-06-15

Family

ID=22973107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00908300T ATE242642T1 (de)	1999-02-24	2000-01-19	Kombinationstherapie für lymphoproliferative krankheiten

Country Status (6)

Country	Link
US (1)	US6316435B2 (de)
EP (1)	EP1156828B1 (de)
AT (1)	ATE242642T1 (de)
AU (1)	AU2967700A (de)
DE (1)	DE60003289T2 (de)
WO (1)	WO2000050082A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003050241A2 (en)	2001-12-12	2003-06-19	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US6841565B1 (en) *	2002-03-29	2005-01-11	The Ohio State University	Treatment of patients with chronic lymphocytic leukemia
US20050207998A1 (en) *	2003-07-21	2005-09-22	Yaoping Lu	Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
EP2946810A1 (de) *	2005-02-03	2015-11-25	TopoTarget UK Limited	Kombinationstherapie mit einem HDAC-Hemmer und Vincristin zur Behandlung von Krebs
AR077975A1 (es)	2009-08-28	2011-10-05	Irm Llc	Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2425830A1 (de) *	2010-09-03	2012-03-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synergistische Arzneimittelkombination zur Behandlung von Krebs
WO2012064671A1 (en)	2010-11-08	2012-05-18	The Ohio State University Research Foundation	Compositions and methods for increasing drug efficacy in cancer
US11007194B2 (en)	2011-11-11	2021-05-18	Array Biopharma Inc.	Method of treating a proliferative disease
WO2013078264A1 (en)	2011-11-23	2013-05-30	Novartis Ag	Pharmaceutical formulations
EP3565549B1 (de)	2017-01-09	2022-03-09	Shuttle Pharmaceuticals, Inc.	Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
EP3737376B1 (de)	2018-01-09	2024-04-17	Shuttle Pharmaceuticals, Inc.	Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen

1999
- 1999-02-24 US US09/256,666 patent/US6316435B2/en not_active Expired - Lifetime
2000
- 2000-01-19 DE DE60003289T patent/DE60003289T2/de not_active Expired - Lifetime
- 2000-01-19 EP EP00908300A patent/EP1156828B1/de not_active Expired - Lifetime
- 2000-01-19 WO PCT/US2000/001180 patent/WO2000050082A1/en not_active Ceased
- 2000-01-19 AU AU29677/00A patent/AU2967700A/en not_active Abandoned
- 2000-01-19 AT AT00908300T patent/ATE242642T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1156828B1 (de)	2003-06-11
US6316435B2 (en)	2001-11-13
EP1156828A1 (de)	2001-11-28
DE60003289T2 (de)	2004-04-29
WO2000050082A1 (en)	2000-08-31
AU2967700A (en)	2000-09-14
DE60003289D1 (de)	2003-07-17
US20010006974A1 (en)	2001-07-05

Legal Events

Date	Code	Title	Description
2003-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
GB9818916D0 (en)	1998-10-21	Use
IL143901A0 (en)	2002-04-21	Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
PT1214936E (pt)	2004-12-31	Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
EE04528B1 (et)	2005-08-15	Teraapias kasutatavad spirofuropridiinide aralklamiinid
MX9700082A (es)	1997-04-30	Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
BR0007527A (pt)	2001-12-04	Fenilfenantridinas com atividade inibitória depde-iv
IL223875A (en)	2017-02-28	Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility
PT880533E (pt)	2002-09-30	Derivados de triazole uteis em terapia
PT797439E (pt)	2003-08-29	Utilizacao de pramipexote como agente neuroprotector
ATE264863T1 (de)	2004-05-15	28-epirapaloge
DE60003289D1 (de)	2003-07-17	Kombinationstherapie für lymphoproliferative krankheiten
PT1143967E (pt)	2005-01-31	Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
BR9911781B1 (pt)	2011-01-25	iluminador para terapia fotodinámica.
TR199800077T1 (xx)	1998-05-21	Kontroll� ��z�len paroksetin terkipleri.
CY1110289T1 (el)	2015-01-14	Φαρμακευτικη συνθεση για τη θεραπεια ρινιτιδων
BRPI0410467A (pt)	2006-05-30	composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE69932510D1 (de)	2006-09-07	Vaskularisierungsinhibitoren
BR9907746A (pt)	2000-10-17	ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
EE9900118A (et)	1999-10-15	H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
DE60023333D1 (de)	2005-11-24	Schaukel für behinderte
DE69721648D1 (de)	2003-06-12	Zuleitung für eine implantierte medizinische Vorrichtung, insbesondere für einen Herzschrittmacher
ATE493106T1 (de)	2011-01-15	Oberflächenbehandlungsmittel für dentales hartgewebe
TR199901546A2 (xx)	2000-04-21	Pirolidinil hidroksamik asid bile�imleri i�in y�ntem.
MD1473F2 (en)	2000-05-31	Antiherpetic remedy
ZA981558B (en)	1998-08-27	Inclusion complexes in aqueous solution